Jefferies analyst Maury Raycroft reiterated a Buy rating and $7 price target on BioCryst Pharma (NASDAQ: BCRX) after spent time ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE